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The objective of this study was to evaluate the interaction of the efflux pump inhibitor 1-(1-
naphthylmethyl)-piperazine (NMP) when combined with different families of antimicrobial agents
against isogenic strains and multidrug-resistant (MDR) Escherichia coli field strains isolated from
animals. Laboratory isogenic strains of E. coli with different levels of expression of efflux pumps
were used as quality controls. Ten MDR E. coli strains were collected from healthy animals in a
cross-sectional study in four commercial dairy farms. The MICs of florfenicol, ciprofloxacin,
tetracycline and ampicillin were determined by a serial microdilution method in Luria–Bertani broth
in the presence or absence of NMP. NMP used with ampicillin exerted no effect on the isogenic or
field strains. In most of the field MDR E. coli strains and in an acrAB-overexpressing (AG112)
isogenic strain, the MICs of florfenicol, ciprofloxacin and tetracycline decreased at least fourfold
when the antimicrobial was combined with the highest NMP concentrations. In the wild-type strain
(AG100), there were no decreases of more than twice the MIC, whilst in strain AG100A, an efflux
pump-deficient strain, the MIC did not change, regardless of the concentration of NMP used with
these three antimicrobials. Thus, ampicillin was not affected by the efflux pump mechanism,
whereas ciprofloxacin, tetracycline and florfenicol were shown to be substrates of efflux pumps,
with a consequent significant reduction in MICs. Resistance could not be completely reversed in
the E. coli field strains by NMP, probably because other resistance mechanisms were also
present. However, in strain AG112, the MIC results demonstrated that NMP expressed an
important synergistic activity with florfenicol. The reduction in florfenicol MIC value was sufficient
to reverse antimicrobial resistance completely for AG112.
INTRODUCTION
Efflux pumps are membrane transporters that are widely
distributed among micro-organisms. These systems can
confer resistance to a given class of drug (specific drug
resistance), but some of them, called multiple drug
resistance (MDR) efflux pumps, can handle a wide variety
of structurally unrelated compounds. Bacterial MDR has
become a serious problem in human and veterinary
medicine, not only in pathogenic but also in commensal
bacteria (Delcour, 2009; Masuda et al., 2000; Moreira et al.,
2004; Nikaido, 1996; Poole, 2005).
MDR in Gram-negative bacteria may be caused by over-
expression of resistance–nodulation–cell division (RND)-
type efflux pumps. These systems are protein exporters
involved in the transport of lipophilic or amphiphilic
molecules or toxic divalent cations with a broad spectrum
of substrates (Renau et al., 2002; Van Bambeke et al., 2003).
RND efflux pumps are organized as multicomponent
systems, in which the efflux pump located in the inner
membrane works in conjunction with a periplasmic fusion
protein and an outer-membrane protein (Van Bambeke
et al., 2003, 2010). The AcrAB multidrug efflux system is
the main efflux pump in Escherichia coli and belongs to the
Abbreviations: EPI, efflux pump inhibitor; MDR, multidrug resistant/
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RND family. This multidrug efflux pump system is
responsible for resistance to tetracycline, chloramphenicol,
ampicillin, nalidixic acid and rifamicin (Moreira et al.,
2004; Nikaido, 1996; Webber & Piddock, 2003).
It has been demonstrated that efflux pump inhibition can
increase intracellular substrate accumulation. For example,
ethidium bromide accumulation assays have been used to
investigate new alternatives to reverse MDR in bacteria
(Kern et al., 2006).
Efflux pump inhibitors (EPIs) are drugs able to modify
resistance by blocking bacterial pumps. Several arylpiper-
idines and other compounds capable of reversing MDR in
E. coli and other members of the Enterobacteriaceae have
been studied extensively (Bean & Wareham, 2009; Bohnert
& Kern, 2005; Coban et al., 2009; Kern et al., 2006).
Phe-Arg-b-naphthylamide (PAbN) is an EPI that has been
studied by a number of authors (Bohnert & Kern, 2005;
Pannek et al., 2006; Sa´enz et al., 2004). It has been shown
that PAbN is able to reverse antimicrobial resistance in
some selected MDR Gram-negative bacteria. However,
PAbN showed intrinsic antibacterial activity against E. coli
strains without expression of AcrAB efflux pumps, and
exerted its effect through additional mechanisms unrelated
to pump inhibition (Bohnert & Kern, 2005; Pannek et al.,
2006; Sa´enz et al., 2004).
Some authors have identified 1-(1-naphthylmethyl)-piper-
azine (NMP) as moderately active in reversing MDR in E.
coli overexpressing RND-type efflux pumps but not in
pump-deficient mutants (Bohnert & Kern, 2005; Kern et
al., 2006; Schumacher et al., 2006). They suggested that
NMP is able to reduce the MICs of two or more antibiotics
in efflux pump-overexpressing strains but has no effect on
efflux pump-deficient strains. Although NMP has been
shown to exhibit less intrinsic activity than PAbN, Bohnert
& Kern (2005) considered that it is the most potent
compound against E. coli.
To date, levofloxacin, tetracycline, chloramphenicol, oxa-
cillin, clarithromycin, rifampicin and linezolid have been
studied in combination with NMP against E. coli (Bean &
Wareham, 2009; Coban et al., 2009; Kern et al., 2006;
Schumacher et al., 2006). However, there are few data
about ampicillin, ciprofloxacin and florfenicol. These are
antimicrobials widely used in veterinary treatments and are
potential antimicrobial resistance selectors.
The objective of this study was to evaluate the interaction
of the EPI NMP when combined with structurally
unrelated antimicrobial agents (e.g. b-lactam antibiotics,
quinolones and tetracyclines) against genetically known
isogenic strains and MDR E. coli field strains isolated from
animals.
METHODS
Bacterial strains. Laboratory strains included a wild-type strain
(AG100) and two isogenic mutants: an RND-type pump-deficient
strain (AG100A) and an acrAB-overexpressing strain (AG112)
with the expression profile of an MDR efflux pump (Cohen et al.,
1993; George & Levy, 1983; Okusu et al., 1996). These three
genetically known isogenic E. coli strains were used as controls for
validating the assay. They were kindly donated by Professor
Hiroshi Nikaido (University of California, Berkeley, CA, USA)
and Laura McMurry (Tufts University School of Medicine,
Boston, MA, USA).
Ten E. coli field MDR isolates were obtained from the faeces of a
variety of healthy animals (dairy cattle, calves and companion
animals) using culturette swabs in a previous cross-sectional study
carried out on four commercial farms in Buenos Aires province
(Tandil, San Vicente, Trenque Lauquen and Luja´n) (Office
International des Epizooties, 2008).
After biochemical typing, strains confirmed to be E. coli and resistant
to three or more antimicrobials were selected as MDR E. coli. E. coli
ATCC 25922 was used as a quality control.
Chemicals and media. NMP was obtained from Sigma-Aldrich.
Luria–Bertani (LB) broth was prepared as 10 g tryptone l–1, 5 g yeast
extract l–1 and10 g NaCl l–1 in distilled water. Ampicillin (96%, w/w)
was from Fluka, tetracycline (97.03%, w/w) and ciprofloxacin
(99.8%, w/w) were from Parafarm and florfenicol (99.3%, w/w)
was from Romikin.
Susceptibility testing. Susceptibility to four different families of
antimicrobial substrates of efflux pump systems (florfenicol, tetra-
cycline, ciprofloxacin and ampicillin) was studied in the presence or
absence of NMP in accordance with the Clinical and Laboratory
Standards Institute guidelines (CLSI, 2008, 2009).
MICs were determined in 96-well microtitre plates using a twofold
standard broth microdilution method (CLSI, 2009) and all determi-
nations were carried out in triplicate. LB broth was used instead of
Mueller–Hinton broth due to lability of the isogenic reference strains.
The antimicrobial dilution series tested for the MDR strains was from
256 to 0.007 mg ml–1. However, for the isogenic strains and E. coli
ATCC 25922, the dilution series varied according to the susceptibility
of the particular strain to the antimicrobial being evaluated.
Each antimicrobial was dispensed alone in the first row of a microtitre
plate and was combined with NMP in the remaining rows. NMP was
tested at five concentrations (6.25, 12.5, 25, 50 and 100 mg ml–1) to
determine its minimum effective concentration (MEC), the minimum
concentration of EPI that produced the maximum reduction in
substrate MIC (Tables 1 and 2).
To measure the antimicrobial activity of NMP, it was also dispensed
alone in the last row for each strain over a dilution range of 1.56–
800 mg ml–1.
An inoculum of each bacterium was prepared by making a direct
saline suspension of colonies selected from a 24 h agar plate. The
suspension was adjusted to match a 0.5 McFarland standard (16108–
26108 c.f.u. ml–1) and then diluted in LB broth to obtain a
concentration of 56104 c.f.u. ml–1 after inoculation in each well
(CLSI, 2008, 2009).
RESULTS
Effect of NMP on the isogenic reference strains
When NMP was combined with ampicillin, there was no
change in MIC for any of the isogenic strains at any of
the NMP concentrations tested, even in the acrAB-
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overexpressing strain, AG112 (Table 1). For the other
antimicrobials studied, MICs were reduced at least
twofold when they were combined with the two higher
concentrations of NMP (50 and 100 mg ml–1) in strains
AG100 (wild-type) and AG112, but were unaffected in
the deletion mutant strain, AG100A.
For florfenicol, a concentration of 50 mg NMP ml–1
reduced the MIC by at least 16-fold in AG112, whilst a
concentration of 100 mg ml–1 reduced it by 32-fold. In the
case of AG100 (wild-type strain), the florfenicol MIC was
reduced four- and eightfold when combined with 50 and
100 mg NMP ml–1, respectively.
For tetracycline, the addition of 50 mg NMP ml–1 decreased
the MIC against AG112 fourfold, whilst 100 mg NMP ml–1
decreased the MIC 16-fold. For AG100, the tetracycline
MIC decreased only twofold in the presence of the EPI, at
the higher concentrations.
Finally, the ciprofloxacin MIC decreased two- and fourfold
against AG112 when it was combined with 50 and 100 mg
NMP ml–1, respectively. For strain AG100, the MIC of
ciprofloxacin decreased twofold with the higher NMP
concentrations, similar to the results for tetracycline.
NMP had no synergistic activity with the antimicrobials
studied against the pump-deficient strain AG100A: there
were no changes in the MICs of the antimicrobials with or
without NMP.
Finally, when NMP was evaluated without antimicrobials,
its MIC was 400 mg ml–1 for all three isogenic strains.
According to the susceptibility breakpoints established by the
Clinical and Laboratory Standards Institute for the anti-
microbials studied, the MECs of NMP in strain AG112 were
50 mg ml–1 for florfenicol and tetracycline and 100 mg ml–1
for ciprofloxacin.
Changes in antimicrobial susceptibility of MDR E.
coli field strains
There were no changes in the MIC of ampicillin in any of
the MDR/ampicillin-resistant E. coli field strains when this
antimicrobial was combined with NMP at any of the
concentrations tested (Table 2), as with the isogenic
control strains.
In most of the MDR/florfenicol-resistant E. coli field
strains, the MIC of florfenicol decreased at least fourfold
when this antimicrobial was combined with the highest
NMP concentrations. With one MDR/florfenicol-resistant
E. coli strain, the florfenicol MIC was reduced eight- and
16-fold with 50 and 100 mg NMP ml–1, respectively (Table
2, sample dairy cattle 1).
For all MDR/tetracycline-resistant E. coli field strains, the
tetracycline MIC was reduced at least fourfold with 100 mg
NMP ml–1. However, when the antimicrobial was com-
bined with 50 mg NMP ml–1, only six of the ten MDR/T
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Table 2. Effect of NMP on antimicrobial MICs for MDR E. coli field strain isolates
STX, Trimethoprim/sulfamethoxazole; see Table 1 for other abbreviations.
Location Sample Resistance phenotype Antimicrobial MIC (mg ml”1) in the presence of NMP (mg ml”1) at: NMP MIC
(mg ml”1)
Fold decrease in MIC
0 6.25 12.5 25 50 100 50
mg NMP ml”1
100
mg NMP ml”1
San Vicente Dairy cattle 1 FLF CIP SXT AMP TET FLF 16 16 16 8 2 1 ¢800 8 16
AMP 256 256 256 256 256 256 ¢800 1 1
CIP 32 32 32 16 8 8 ¢800 4 4
TET 64 64 64 32 16 16 ¢800 4 4
Dairy cattle 2 FLF SXT TET FLF 256 256 128 128 64 64 ¢800 4 4
TET 256 128 128 128 64 32 ¢800 4 8
Luja´n Dog 1 FLF SXT AMP TET FLF 256 256 256 256 128 128 ¢800 2 2
AMP 256 256 256 256 256 256 ¢800 1 1
TET 256 256 256 128 128 64 ¢800 2 4
Dog 2 SXT AMP TET AMP 256 256 256 256 256 256 ¢800 1 1
TET 128 128 128 64 64 32 ¢800 2 4
Trenque
Lauquen
Dairy cattle 1 FLF SXT TET FLF 256 128 128 128 64 64 ¢800 4 4
TET 64 64 64 32 16 16 ¢800 4 4
Dairy cattle 2 FLF AMP TET FLF 256 128 128 128 64 64 ¢800 4 4
AMP 256 256 256 256 256 256 ¢800 1 1
TET 256 256 128 128 64 64 ¢800 4 4
Calf 1 CIP AMP TET AMP 256 256 256 256 256 256 ¢800 1 1
CIP 128 128 128 64 64 32 ¢800 2 4
TET 256 256 256 256 64 64 ¢800 4 4
Calf 2 CIP AMP TET AMP 256 256 256 256 256 256 ¢800 1 1
CIP 128 128 128 64 64 32 ¢800 2 4
TET 256 256 256 128 128 64 ¢800 2 4
Calf 3 CIP AMP TET AMP 256 256 256 256 256 256 ¢800 1 1
CIP 128 128 128 64 64 32 ¢800 2 4
TET 256 256 256 128 128 64 ¢800 2 4
Calf 4 CIP AMP TET AMP 256 256 256 256 256 256 ¢800 1 1
CIP 128 128 128 64 32 32 ¢800 4 4
TET 256 256 128 128 64 64 ¢800 4 4
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tetracycline-resistant E. coli strains achieved the same MIC
reduction.
In the case of ciprofloxacin, a concentration of 100 mg ml–1
of the EPI was able to produce a fourfold reduction in the
MIC of the quinolone in all of the MDR/ciprofloxacin-
resistant E. coli field strains. However, the combination of
ciprofloxacin with 50 mg NMP ml–1 produced a similar
result only in two of the studied strains.
The MIC of NMP without antimicrobial was¢800 mg ml–1
in all of the MDR E. coli field strains.
DISCUSSION
As shown by the MIC results, ampicillin was not affected
by efflux pump overexpression in E. coli. Although several
authors have reported that b-lactams are substrates of RND
efflux pumps (Li et al., 1998; Nakae et al., 1999), in the
present study, inhibition of the EPI did not affect the
MIC results. The combination of efflux pump systems with
b-lactamase enzymes allows bacteria to avoid enzymic
saturation, collaborating in antimicrobial resistance (Bina
et al., 2009; Mazzariol et al., 2000; Nakae et al., 1999; Van
Bambeke et al., 2003, 2010).
Although strain AG112 is not an important b-lactamase
producer, it can express an ampicillin-resistant pheno-
type. However, the efflux system by itself is unable to
express high resistance levels against b-lactams (Bina
et al., 2009; Li et al., 1998; Lomovskaya et al., 2001; Nakae
et al., 1999).
In contrast, the MIC results demonstrated that florfeni-
col, tetracycline and ciprofloxacin are common substrates
of efflux pump systems. In general, when combining
antimicrobials with NMP at the highest concentrations
(50 and 100 mg ml–1), the MICs decreased at least
fourfold, not only in the isogenic E. coli strains but also
in the E. coli field isolates with an MDR phenotype.
Similar results have been obtained by some authors for
the MICs of fluoroquinolones with NMP and other EPIs
against Pseudomonas aeruginosa (Kriengkauykiat et al.,
2005; Lomovskaya et al., 2001; Renau et al., 2002) and E.
coli (Kern et al., 2006; Sa´enz et al., 2004; Schumacher
et al., 2006).
As efflux pump overexpression is the only resistance
mechanism present in strain AG112, the MIC results
demonstrated that NMP expressed an important syn-
ergistic activity with florfenicol. The reduction in MIC
value was sufficient to completely reverse the antimicrobial
resistance of this strain.
In most cases, the MEC of NMP was 50 mg ml–1, and it was
100 mg ml–1 in the rest of the strains (Table 2).
Several studies have used 100 mg NMP ml–1 in E. coli
(Bohnert & Kern, 2005; Kern et al., 2006; Schumacher
et al., 2006), Acinetobacter baumannii (Pannek et al., 2006)
and Campylobacter species (Hannula & Ha¨nninen, 2008) to
obtain better inhibition in RND-type overexpressing efflux
pump systems.
The result of the MIC of NMP without an antimicrobial
revealed that this EPI had no intrinsic antimicrobial
activity, even at high concentrations, agreeing with the
results of other authors (Kern et al., 2006; Pannek et al.,
2006).
Despite the important decrease observed in the MIC values
of florfenicol, tetracycline and ciprofloxacin in the MDR E.
coli field strains, combinations of antimicrobial and NMP
were unable to completely reverse the antimicrobial
resistance.
Our demonstration of the inhibitory effect of NMP against
MDR E. coli field strains requires genotypic confirmation.
Further studies are planned to explore other mechanisms
that may have contributed to MDR in our strains such as
target mutations, b-lactamase production and loss of
outer-membrane porins.
Conclusion
There is increasing evidence for a significant role of efflux
pumps in antibiotic resistance in bacteria (Elkins &
Nikaido, 2002; Everett et al., 1996; Nikaido et al., 2008;
Van Bambeke et al., 2003; Ziha-Zarifi et al., 1999). In the
present study, we demonstrated that the EPI NMP can
partially reverse antimicrobial resistance in MDR E. coli
field strains. This probably occurs because efflux pump
overexpression by itself is unable to express a high-level
resistance phenotype. In contrast, the association of
overexpression of these genes with other antimicrobial
resistance mechanisms may confer not only high-level but
also broad-spectrum resistance (Van Bambeke et al., 2003;
Webber & Piddock, 2003).
In contrast, we demonstrated that inhibition of efflux
pump overexpression had a significant role in florfenicol
resistance. NMP could be a promising tool to reverse
antimicrobial resistance completely when florfenicol is
expressed in bacteria with an MDR phenotype.
The effect of efflux pumps needs to be considered in the
design of future antibiotics and the role of inhibitors
assessed in order to maximize the efficacy of current and
future antimicrobials.
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